Incyte (INCY) Sell-Off on Opzelura Miss an 'Overreaction' - Truist

August 2, 2022 12:45 PM EDT Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), saying the stock ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login